Evidence map›Paper›PMID 33411057›Full record

ArticleOral and maxillofacial surgery2021

Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: a case report.

Yoshinari Myoken, Yoshinori Fujita, Ryota Imanaka, Shigeaki Toratani

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Oral and maxillofacial surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Clinical Spectrum of Bosutinib Related Side Effects in a Patient of CML: A Case Report and Review of Literature.International journal of hematology-oncology and stem cell research · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yoshinari MyokenDepartment of Oral Surgery, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Senda-machi, Naka-ku, Hiroshima, 730-0052, Japan. myoken@do5.enjoy.ne.jp.
Yoshinori FujitaDepartment of Oral Surgery, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Senda-machi, Naka-ku, Hiroshima, 730-0052, Japan.
Ryota ImanakaDepartment of Hematology, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Shigeaki TorataniDepartment of Molecular Oral Medicine and Maxillofacial Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon adverse drug reaction that can be induced by certain therapeutic drugs, including antiresorptive and antiangiogenic agents. Here, we describe the first case of ONJ induced by bosutinib, a tyrosine kinase inhibitor, in a patient with chronic myeloid leukemia (CML) who was not taking an antiresorptive agent. A 65-year-old male with no history of either antiresorptive treatment or dental surgery but diagnosed with CML had been undergoing treatment with bosutinib for 2 years. He developed right mandibular stage 2 osteonecrosis. The patient eventually underwent extensive surgery consisting of removal of the necrotic bone and infected soft tissue in combination with nasolabial flap reconstruction. He obtained complete resolution of MRONJ at 12 months postoperatively. As new cancer therapies become available, it is important that clinicians are aware of this novel case of bosutinib-induced ONJ in a patient undergoing CML treatment.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveOsteonecrosisQuinolinesAgedAniline CompoundsDiphosphonatesHumansMaleNitrilesAniline CompoundsBone Density Conservation AgentsbosutinibDiphosphonatesNitrilesQuinolinesBosutinibChronic myeloid leukemiaLocal flapsMedication-related osteonecrosis of the jaw

Identifiers

PMID33411057
OpenAlexW3118959909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.